Mesoblast (ASX:MSB) Interest Received: A$6.87 Mil (TTM As of Dec. 2025)


ASX:MSB Mesoblast Ltd ASX:MSB
42 GF Score
Price A$2.08
! 4 Warning Signs
View Full Analysis

What is Mesoblast Interest Received?

Mesoblast ASX:MSB +0.97% 42 Interest Received is A$6.87 Mil as of Dec. 2025. GuruFocus rates ASX:MSB with a GF Score™ of 42/100. The stock has 4 warning signs investors should review.

Mesoblast's Interest Received for the three months ended in Dec. 2025 was A$1.73 Mil.

Mesoblast's Interest Received for the trailing twelve months (TTM) ended in Dec. 2025 was A$6.87 Mil.

Mesoblast Interest Received Related Terms

Mesoblast Interest Received Historical Data

* Premium members only.

The historical data trend for Mesoblast's Interest Received can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesoblast Interest Received Chart

Mesoblast Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Interest Received
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.01 1.19 2.68 5.45

Mesoblast Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Received Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.34 2.51 2.27 1.73 0.38
ASX:MSB
42GF Score
Mesoblast Ltd ASX:MSB
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mesoblast Interest Received Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Interest Received represents interest received by the company in the direct cash flow method.

Interest Received for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was A$6.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Received →
What does a Interest Received of A$6.87 Mil mean?
Mesoblast (ASX:MSB) has a Interest Received of A$6.87 Mil as of Dec. 2025. Interest Received represents interest received by the company in direct cash flow method. View historical data for Mesoblast and its competitors.
Is Mesoblast's Interest Received too high?
Mesoblast's current Interest Received is A$6.87 Mil. Overall, Mesoblast has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's Interest Received compare to VRTX and REGN?
Mesoblast's Interest Received of A$6.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Received for a Biotechnology company?
A good Interest Received depends on the Biotechnology industry context. However, Interest Received should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Received mean?
A high Interest Received can signal that a stock is expensive relative to its fundamentals. Interest Received represents interest received by the company in direct cash flow method. View historical data for Mesoblast and its competitors. Mesoblast's current Interest Received is A$6.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (ASX:MSB) has a current Interest Received of A$6.87 Mil. The current Interest Received is A$6.87 Mil. Mesoblast's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Received calculated?
Interest Received is calculated from a company's financial statements. For Mesoblast (ASX:MSB), the current Interest Received is A$6.87 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
42GF Score

Get the complete analysis for ASX:MSB

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.08
Price